Strategies of neoadjuvant therapy in esophageal cancer: a study on the effects of treatment frequency and surgery interval
Surgical interval of less than six weeks following neoadjuvant chemoimmunotherapy is associated with improved disease-free survival and a trend toward better OS. While treatment cycle number exhibited no significant impact on survival. But these findings warrant further validation through multicenter prospective trials.
Authors
- Huilai Lv (ORCID: https://orcid.org/0000-0002-2795-9751)
- B. Chen
- Kyung Hoon Sun (ORCID: https://orcid.org/0000-0001-5473-9781)
- Mingbo Wang
- Chunyue Gai
- Zhenhua Li (ORCID: https://orcid.org/0000-0002-9648-0517)
- Fan Zhang (ORCID: https://orcid.org/0000-0003-1154-8939)
- Yü Liu (ORCID: https://orcid.org/0000-0003-2211-3535)
- Ziqiang Tian (ORCID: https://orcid.org/0000-0002-3091-313X)
- Yonggang Zhu (ORCID: https://orcid.org/0000-0001-7431-9282)
- W Ding
Institutions
- Hebei Medical University (CN)
- Hebei University of Economics and Business (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fonc.2025.1642765
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Hebei Province